3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Myelodysplastic Syndromes
6
Leukemia, Myeloid, Acute
5
Leukemia
3
Hodgkin Disease
3
Lymphoma, Non-Hodgkin
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Lymphoma
1
Leukemia, Prolymphocytic
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Graft vs Host Disease
1
Congenital Abnormalities
1
Blast Crisis
1
Interventions
Cyclophosphamide
38
Tacrolimus
35
Methotrexate
29
fludarabine phosphate
24
Busulfan
24
Cyclosporine
23
Antilymphocyte Serum
23
Mycophenolic Acid
20
fludarabine
18
Peripheral Blood Stem Cell Transplantation
18
Melphalan
18
Methylprednisolone
16
Filgrastim
16
Radiotherapy
15
Sirolimus
14
Whole-Body Irradiation
13
thymoglobulin
8
Stem Cell Transplantation
8
Thiotepa
7
Cord Blood Stem Cell Transplantation
7
Granulocyte Colony-Stimulating Factor
6
Transplantation
5
Hematopoietic Stem Cell Transplantation
5
Flow Cytometry
5
Etoposide
5
Alemtuzumab
5
Cyclosporins
4
Bone Marrow Transplantation
4
Therapeutics
3
Prednisone
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Graft vs Host Disease
×
Radiation
×
Myeloid
×
Clear all
NCT04678401
2025-10-20
IS-free Treg HaploHCT
Dana-Farber Cancer Institute
Phase 1
Recruiting
30 enrolled